|
Orthologous residues
|
|
BAD (human): S75‑p, BAD (mouse): S112‑p, BAD (rat): S113‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout], FDCP-1 (myeloid), Jurkat (T lymphocyte), U2OS (bone cell) [GR (human)]
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Comments:
Human Pim2 was entered instead of mouse one
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Pim2 (human)
|
transfection of inactive enzyme, genetic transfer of wild-type enzyme
|
Human Pim2 was entered instead of mouse one
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
IL-3
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
apoptosis, inhibited
|